Penserra Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Penserra Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Buy	+726	New	+$34.9K	﹤0.01%	845
2021 Q4	–	Sell	-1,215	Closed	-$32K	–	1542
2021 Q3	$32K	Buy	1,215 +10	+0.8%	+$268	﹤0.01%	1171
2021 Q2	$37K	Buy	1,205 +15	+1%	+$460	﹤0.01%	1068
2021 Q1	$31K	Sell	1,190 -20	-2%	-$559	﹤0.01%	902
2020 Q4	$30K	Buy	1,210 +758	+168%	+$16.3K	﹤0.01%	782
2020 Q3	$9K	Buy	+452	New	+$10.3K	﹤0.01%	826
2018 Q3	–	Sell	-244,371	Closed	-$29M	–	745
2018 Q2	$29M	Buy	+244,371	New	+$12.7M	1.83%	13

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Penserra Capital Management's SUPN Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 726 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #845 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in SUPN as recently as Q3 2021.

Penserra Capital Management first reported a position in SUPN in Q2 2018 and has held it in 7 quarters since. The position peaked at $29M in Q2 2018. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Penserra Capital Management held 726 shares of Supernus Pharmaceuticals worth $33K as of Q2 2026.
Supernus Pharmaceuticals was a new Penserra Capital Management position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #845 holding.
Penserra Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2018 and has held it in 7 quarters since.
Penserra Capital Management's Supernus Pharmaceuticals position peaked at $29M in Q2 2018.
335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.